The phase III MARIPOSA2 trial confirmed the clinical benefit of amivantamab, a bispecific anti-EGFR/MET antibody, in combination with chemotherapy after disease progression on osimertinib in an EGFR-mutated NSCLC population [24]. This evidence concerns the gene MET and non-small cell lung carcinoma.